NCT06734676Completed
fMRI-guided Transcranial Magnetic Stimulation Treatment for Parkinson's Disease
Study of Multi-Modal Imaging Technology in MRI-Guided Transcranial Magnetic Stimulation Treatment for Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 16 Dec 2024
Brief summary (registry, in English)
The goal of this clinical trial is to compare the efficacy of targeting the newly discovered SCAN versus traditional effector-specific networks in M1 using multimodal imaging and rTMS in patients with Parkinson's disease. The main question it aims to answer is: Is rTMS targeting the SCAN more effective than rTMS targeting effector networks?
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 36 (actual)
- First submitted
- 11 Dec 2024
- Start date
- 29 May 2023
- Primary completion date
- 28 Apr 2024
- Lead sponsor
- Changping Laboratory
- Diseases
- Parkinson disease
- NCT number
- NCT06734676
What you commit to
- Study type: Interventional
- Participants enrolled: 36
- From 29 May 2023 to the primary completion date, 28 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Implanted medical devices incompatible with MRI, such as deep brain stimulators, pacemakers, cochlear implants, or vagus nerve stimulators.
- Prior neuromodulation treatments (e.g., TMS, transcranial electrical stimulation, transcranial ultrasound stimulation) within the last three months.
Other illness
- Diagnosed with other neurological diseases, such as stroke, brain tumor, traumatic brain injury, motor neuron disease, Alzheimer's disease, multiple sclerosis, etc.
- Conditions contraindicated for MRI, such as claustrophobia, tattoos, or magnetic metal implants.
- Personal or family history of epilepsy.
Other
- Other health abnormalities that the investigator deems unsuitable for study participation.
Who the study is looking for
- Diagnosis of primary PD per the MDS Clinical Diagnostic Criteria (2015) or the Chinese Parkinson's Disease Diagnostic Criteria (2016).
- Age 18-75.
- Stable use of anti-PD medication for at least two months prior to enrollment.
- Normal cognitive function (MMSE \> 24).
- Understanding of the study and signing of informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Henan Provincial People's Hospital Coordinator of this site? Confirm its status | Zhengzhou | China | Unknown status |
Related publications
- Parkinson's disease as a somato-cognitive action network disorder.Nature · 2026 · PMID 41639440
This page is information, not medical advice. Discuss any trial with your doctor.